• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study.

作者信息

Georgakopoulos J R, Lam K, Sandhu V K, Ighani A, Phung M, Piguet V, Yeung J

机构信息

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.

Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

出版信息

J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e416-e418. doi: 10.1111/jdv.16366. Epub 2020 May 8.

DOI:10.1111/jdv.16366
PMID:32176394
Abstract
摘要

相似文献

1
Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study.生物制剂优特克单抗、司库奇尤单抗和依奇珠单抗治疗斑块状银屑病的12周疗效和安全性比较：一项真实世界多中心回顾性研究。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e416-e418. doi: 10.1111/jdv.16366. Epub 2020 May 8.
2
Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.在英国，以司库奇尤单抗为对照，优时比单抗序贯生物治疗作为中重度银屑病一线治疗的成本效益分析
J Med Econ. 2018 Aug;21(8):810-820. doi: 10.1080/13696998.2018.1474747. Epub 2018 Jun 6.
3
Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.治疗一年后，中度至重度银屑病患者使用司库奇尤单抗与优特克单抗实现皮肤清除的对比：真实世界实践
Dermatol Ther. 2020 Nov;33(6):e14202. doi: 10.1111/dth.14202. Epub 2020 Sep 7.
4
Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.真实世界中生物制剂治疗中重度斑块状银屑病的疗效：对台湾 75 例患者的分析。
PLoS One. 2020 Dec 29;15(12):e0244620. doi: 10.1371/journal.pone.0244620. eCollection 2020.
5
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.司库奇尤单抗在清除中重度斑块型银屑病患者皮肤方面优于乌司奴单抗：来自 CLEAR 研究的结果。
J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9. doi: 10.1016/j.jaad.2016.08.008. Epub 2016 Sep 20.
6
Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.接受ixekizumab、etanercept和ustekinumab治疗的中重度银屑病患者治疗中出现的湿疹样反应的综合安全性分析。
Br J Dermatol. 2021 Oct;185(4):865-867. doi: 10.1111/bjd.20527. Epub 2021 Aug 10.
7
Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.依奇珠单抗治疗真实世界斑块型银屑病患者的疗效和安全性初步结果：一项多中心回顾性研究。
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):553-559. doi: 10.1111/jdv.15288. Epub 2018 Nov 13.
8
An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis.IXORA-S中患者报告结局的分析：中度至重度银屑病患者使用司库奇尤单抗与优特克单抗52周的比较
Acta Derm Venereol. 2020 Dec 9;100(19):adv00344. doi: 10.2340/00015555-3700.
9
Ixekizumab for the treatment of psoriasis: up-to-date.依奇珠单抗治疗银屑病：最新进展。
Expert Opin Biol Ther. 2020 Jun;20(6):549-557. doi: 10.1080/14712598.2020.1729736. Epub 2020 Mar 10.
10
Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.司库奇尤单抗（白细胞介素17A拮抗剂）：真实世界临床实践中的12周疗效和安全性结果
J Cutan Med Surg. 2019 Mar/Apr;23(2):174-177. doi: 10.1177/1203475418814229. Epub 2018 Nov 18.